A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.
Also called NCT02025907
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 218 participants
- Registry
-
NCT02025907 -
2013-004819-40
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, France, Germany
- Registry status
- Completed
Technical summary
Registry record NCT02025907. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2016-09-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Canagliflozin, 100 mg
- Intervention (Drug)
- Canagliflozin, 300 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct02025907- Content hash
d4fb2f609530e88c234411e75fb647d54edb6d1121d445082ea5c9ed1fff3b84